The Pharma Data

JANUARY 11, 2021

11, 2021 — As the rollout of the COVID-19 vaccines continues, scores of questions are emerging. How do the COVID-19 vaccines work? The COVID-19 vaccines work by teaching the immune system to protect against the virus, experts said. This protein then appears on the surface of the cell and the immune system responds to it.

Vaccination 52

Vaccination Vaccine Allergies Protein 52

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. This groundbreaking endeavor has received support from the National Institute of Allergy and Infectious Diseases (NIAID). Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

XTalks

SEPTEMBER 8, 2020

The company has signed on to help manufacture AstraZeneca’s COVID-19 vaccine candidate, AZD1222, intended to protect against the SARS-CoV-2 novel coronavirus. AMRI is proud to partner with AstraZeneca in pursuit of a vaccine that could protect people against the coronavirus pandemic,” said John Ratliff, CEO of AMRI, in a statement.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

Scienmag

AUGUST 20, 2020

Credit: NIAID Immunization of mice with a new vaccine consisting of fungal particles loaded with Staphylococcus aureus (S. aureus) proteins protects mice against S. aureus is one of the […].

Vaccination 98

Vaccination Vaccine Protein Allergies 98

XTalks

NOVEMBER 6, 2020

Canadian clinical-stage biotech company Symvivo Corporation has developed an oral COVID-19 vaccine that entered clinical trials this week. The first healthy volunteer was dosed with the vaccine in Australia as part of the bacTRL-Spike COVID-19 Phase I clinical trial. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Scienmag

MARCH 15, 2021

The first vaccine has been administered in a comparative adjuvant trial of DNA prime/protein boost HIV vaccine regimens in Kericho, Kenya Credit: U.S. Military HIV Research Program SILVER SPRING, Md.

Vaccination 68

Vaccination Vaccine Trials DNA 68

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . The Phase I trial (IAVI G001) tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing.

Vaccination 52

Vaccination Vaccine Trials Antibody 52

XTalks

JANUARY 27, 2021

COVID-19 vaccine maker Moderna announced this week that results from a study show that the shot is effective against some of the new circulating variants of SARS-CoV-2. In a news release from Moderna, the company reported that the administration of its COVID-19 vaccine induced antibody titers against both variants.

Vaccination 52

Vaccination Vaccine In-Vitro Protein 52

Drug Discovery World

MARCH 23, 2023

The quality of CD8+ T cell response to two doses of the Pfizer-BioNTech Covid-19 vaccine was considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, the US study found. The Pfizer-BioNTech vaccine uses parts of the SARS-CoV-2 spike protein to elicit an immune response without causing infection.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52

The Pharma Data

SEPTEMBER 1, 2020

AstraZeneca has started a Phase 3 trial of its experimental coronavirus vaccines in the US, making it the third company to start late-stage trials of a vaccine. . The trial will see participants receive either two doses of the vaccine or a placebo. Photo by Daniel Paquet from Regina, Canada.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

pharmaphorum

SEPTEMBER 1, 2020

AstraZeneca has expanded development of COVID-19 vaccine AZD1222 into the US, beginning a phase 3 clinical trial across all adult age groups. Participants are being randomised to receive two doses of either AZD1222 or a saline control, four weeks apart, with twice as many participants receiving the potential vaccine than the saline control.

Vaccination 63

Vaccination Vaccine Trials Immune Response 63

Scienmag

APRIL 22, 2021

In February, the researchers introduced […].

Production 84

Production Vaccination Vaccine Protein 84

Drug Discovery World

JANUARY 21, 2024

As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay. As a vaccine immunologist Kanekiyo’s primary research interests are structure-based vaccine design, viral immunity, and host-pathogen interplay.

Protein 52

Protein Vaccination Vaccine Development 52

Scienmag

JULY 23, 2021

Vaccines against COVID-19, which […].

Antibody 75

Antibody Protein Vaccination Vaccine 75

The Pharma Data

DECEMBER 14, 2020

ICU nurse Sandra Lindsay, with Long Island Jewish Medical Center in Queens, New York, received the Pfizer-BioNTech COVID-19 vaccine. Food and Drug Administration (FDA) ’ s Vaccines and Related Biological Products Advisory Committee on Thursday, December 17. Both vaccines have demonstrated about 94-95% efficacy in clinical trials.

Vaccination 52

Vaccination Vaccine Allergies Genome 52

Scienmag

MARCH 4, 2021

A deep sequencing study of 747 SARS-CoV-2 virus isolates has revealed mutant peptides derived from the virus that cannot effectively bind to critical proteins on the surface of infected cells and, in turn, hamper activation of CD8+ killer T cells that recognize and destroy these infected cells.

Protein 54

Protein Allergies Vaccination Vaccine 54

The Pharma Data

DECEMBER 17, 2020

Food and Drug Administration (FDA) ’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended the agency grant Moderna ’s COVID-19 vaccine emergency use authorization (EUA). A week ago, the FDA granted Pfizer-BioNTech’s COVID-19 vaccine EUA on Friday the day after the same adcom voted 16-1-1.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

Scienmag

JUNE 25, 2021

Changes to the ‘spike’ protein explain Alpha’s faster spread, and how the Beta variant evades immune responses, suggesting the need for a booster with an updated vaccine Credit: Bing Chen, PhD, Boston Children’s Hospital New SARS-CoV-2 variants are spreading rapidly, and there are fears that current COVID-19 vaccines won’t (..)

Immune Response 75

Immune Response Vaccination Vaccine Protein 75

Scienmag

JULY 6, 2021

Studies reveal unprecedented mechanism behind loss of antibody neutralization against this pandemic coronavirus variant of concern Credit: Young-Jun Park, UW Department of Biochemistry Three mutations in the Epsilon coronavirus spike protein dampen the neutralizing potency of antibodies induced by current vaccines or past COVID infections.

Antibody 98

Antibody Protein Vaccination Vaccine 98

Pfizer

JULY 26, 2022

Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design. deliesschef.

Vaccination 111

Vaccination Vaccine Protein Immune Response 111

Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month. The BET inhibitor worked by increasing beta-3 tubulin (TUBB3), a protein found in brain metastases.

Vaccination 53

Vaccination Vaccine Research Trials 53

pharmaphorum

JULY 7, 2022

In the second of a three-part series, Ben Hargreaves looks at the importance of early-stage research into various emerging infectious disease threats and how it saved precious time in the work to develop a working vaccine during the current pandemic. The institute also led and funded early-stage clinical research into the vaccine candidate.

Vaccination 103

Vaccination Vaccine Development Research 103

The Pharma Data

NOVEMBER 17, 2020

Mymetics continues to progress its Covid-19 vaccine development plan based on its virosome-vaccine platform. This new study will complement Mymetics’ other preclinical Covid-19 studies that are ongoing at Baylor College of Medicine in Texas USA and the Helmholtz Center of Infection Research in Germany.

Vaccination 40

Vaccination Vaccine Containment Immune Response 40

Drug Discovery World

JANUARY 22, 2024

Entact Bio is using a platform to develop enhancement-targeting chimeric (ENTAC) molecules, which bring together target proteins with enzymes called deubiquitinating enzymes (DUBs). The impact of this technology on the patients for which it is being implemented is multifaceted.

Engineer 59

Engineer Immune Response Drugs Vaccination 59

Delveinsight

JANUARY 21, 2021

Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. The combination appears to work by activation of the tumour-suppressing protein p53, they announced. The gene TP53 produces the protein p53, a known tumour suppressor.

Research 52

Research Protein Clinical Trials Clinical Trials 52

Scienmag

OCTOBER 23, 2020

The technique should help in the design of vaccines against HIV, SARS-CoV-2 and other viruses that cloak their outer proteins with sugars to evade antibodies.

Protein 61

Protein Antibody Scientist Vaccination 61

The Pharma Data

NOVEMBER 16, 2020

and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 8, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Swiss Federal Government has increased its confirmed order commitment from 4.5 million doses of Moderna’s vaccine candidate against COVID-19 , mRNA-1273. “As

Vaccination 40

Vaccination Vaccine Manufacturing Containment 40

The Pharma Data

MARCH 13, 2022

People who gained immunity – either through vaccination or exposure – against the original strain of SARS-CoV-2, the virus that causes COVID-19, also are likely to have some protection against the pathogen’s omicron variant. Singapore biotechnology company. population.

Immune Response 52

Immune Response Protein Medicine Genetics 52

XTalks

NOVEMBER 30, 2023

Its mechanism of action involves blocking the protein shell (capsid) of the HIV-1 virus, disrupting multiple crucial stages of the viral lifecycle. Promising HIV Vaccines in Clinical Trials Advancements in preventable therapeutic options for HIV are currently in progress. In November 2023, Hookipa Pharma Inc.,

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

MARCH 24, 2021

76% vaccine efficacy against symptomatic COVID-19. Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. 100% efficacy against severe or critical disease and hospitalisation.

Radiology 52

Radiology Vaccination Vaccine Trials 52

The Pharma Data

MARCH 22, 2021

79% vaccine efficacy at preventing symptomatic COVID-19. The AstraZeneca US Phase III trial of AZD1222 demonstrated statistically significant vaccine efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalisation. The trial had a 2:1 randomisation of vaccine to placebo.

Trials 52

Trials Vaccination Vaccine Radiology 52

Scienmag

MAY 13, 2021

The new […].

Immune Response 53

Immune Response Antibody Protein Vaccination 53

pharmaphorum

APRIL 28, 2021

The RNA interference (RNAi) drug is designed to treat haemophilia A and B patients by suppressing antithrombin (AT), a protein that inhibits blood clotting. The aim is to increase the generation of thrombin – a major component of the clotting cascade – and normalise clot formation. rise to €915 million.

Drugs 52

Drugs Sales Allergies RNA 52

Pharmaceutical Technology

AUGUST 5, 2022

As per the prevailing prion theory, a misfolded version of a normal cell-surface protein acts as the chief infectious agent. There is an enormous emphasis on prion protein and prion protein folding,” says Dr. Laura Manuelidis, professor of neuropathology at the Yale School of Medicine. “If

Drugs 299

Drugs Protein Vaccination Vaccine 299

The Pharma Data

DECEMBER 23, 2020

” Dr. Stanley Plotkin , Professor Emeritus at The Wistar Institute, said, “INOVIO’s DNA vaccine appeared to be quite safe with few significant reactions but yet induced both antibody and T cell responses to SARS-CoV-2.” . PLYMOUTH MEETING, Pa. , The participants were enrolled into 1.0

DNA 40

DNA Vaccination Vaccine Immune Response 40

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105